A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

计划入组 372 人 · 首次发布于 2023 年 6 月 18 日

Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients

计划入组 28 人 · 首次发布于 2021 年 12 月 13 日

The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage

计划入组 50 人 · 首次发布于 2021 年 8 月 20 日

Adalimumab(Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma, Halimatoz)

Rx

repurposed adalimumab

AAV2.adalimumab

Bio-Thera Solutions, Ltd.

Ryvu Therapeutics SA

Poland

HENLIUS

China

Ten Adalimumab Biosimilars Now Available in US Market Following Latest FDA Approval

Regeneron Appeals Eylea Biosimilar Ruling; Prime Therapeutics Adds Humira Biosimilars; Denosumab Biosimilar Advances

FDA Approves Alvotech and Teva's SELARSDI (ustekinumab-aekn) for Crohn's Disease and Ulcerative Colitis